What Challenges Exist in Targeting M1 Macrophages for Cancer Therapy?
Several challenges exist in targeting M1 macrophages for cancer therapy. One major challenge is the heterogeneity of the TME, which can vary widely between different types of tumors and even within the same tumor over time. This heterogeneity can affect the efficacy of therapies aimed at modulating macrophage polarization. Another challenge is the potential for systemic inflammation or autoimmunity due to the widespread activation of M1 macrophages. Therefore, strategies to selectively target the TME while minimizing systemic effects are needed.
